Actively Recruiting
Peripheral Neuropathy in Adults Receiving Enfortumab Vedotin and Pembrolizumab Perioperative Systemic Therapy for Muscle-Invasive Urothelial Carcinoma A Prospective, Multicenter, Non-Interventional Observational Trial
Led by Comprehensive Cancer Center Munich (CCCM) · Updated on 2026-10-13
79
Participants Needed
3
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing adults with muscle-invasive urothelial carcinoma who receive perioperative treatment with enfortumab vedotin and pembrolizumab as part of their routine clinical care. The study aims to understand how peripheral neuropathy develops, changes, and whether symptoms remain after treatment. It also evaluates neuropathic pain, quality of life, depressive symptoms, and changes in taste and smell, using both patient reports and objective tests. Participants receive enfortumab vedotin and pembrolizumab during neoadjuvant and adjuvant treatment phases, along with radical cystectomy surgery as part of standard care. Assessments occur before treatment, during both treatment phases, around surgery, and at the end of treatment to monitor neurological and neurophysiological changes. Throughout the study, participants complete questionnaires, undergo neurological examinations, nerve conduction studies, and taste testing. Researchers measure changes in peripheral neuropathy symptoms, neuropathic pain, quality of life, depressive symptoms, and sensory functions. The study monitors participants until the end of treatment to better understand symptom progression and persistence.
CONDITIONS
Brief Title
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here